Takeda reports real-world data for vedolizumab in inflammatory bowel disease

Takeda is presenting real-world study data this week showing the benefits its drug vedolizumab can offer in the treatment of inflammatory bowel disease.

The company is attending United European Gastroenterology (UEG) Week in Vienna, which runs from October 16th to 19th, sharing new research findings highlighting the effectiveness and safety of vedolizumab in patients with moderately to severely active ulcerative colitis and Crohn's disease.

These will include data from a systematic review of 51 real-world studies, describing 5,775 patients treated with vedolizumab, the majority of whom were refractory to prior anti-tumour necrosis factor therapies.

Vedolizumab was shown to be associated with a range of benefits, including improved clinical remission rates, reductions in disease activity scores and enhanced mucosal healing.

Dr Sharon O'Byrne, vice-president and global medical head for Takeda's gastrointestinal division, said: "The real-world data on vedolizumab presented at UEG Week continue to support and build physician confidence in its effectiveness in the management of ulcerative colitis and Crohn's disease."

Also being presented during UEG Week is clinical data comparing the performance of Takeda's drug to an alternative, infliximab.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.